{"id":{"repo_id":"sask","oai_identifier":"oai:harvest.usask.ca:10388/etd-03292011-144232"},"canonical_url":"https://search.dev.ndltd.org/etd/sask/oai:harvest.usask.ca:10388/etd-03292011-144232","repository":{"repo_id":"sask","name":"University of Saskatchewan","base_url":"https://harvest.usask.ca/server/oai/request"},"display":{"title":"Antihypertensive effects of sulforaphane","abstract":"Persistent hypertension is associated with a greater incidence of organ damage and conditions such as stroke, heart failure and end–stage kidney disease, which results in increased cardiovascular (CV) morbidity and mortality. Among the patients receiving antihypertensive treatment, the level of adequate blood pressure (BP) control (","abstract_html":"Persistent hypertension is associated with a greater incidence of organ damage and conditions such as stroke, heart failure and end–stage kidney disease, which results in increased cardiovascular (CV) morbidity and mortality. Among the patients receiving antihypertensive treatment, the level of adequate blood pressure (BP) control (","abstract_has_math":false,"creators":["Banigesh, Ali"],"institution":"University of Saskatchewan","degree_name":"Doctor of Philosophy (Ph.D.)","degree_level":"Doctoral","degree_discipline":"Pharmacology","degree_department":null,"school":null,"contributors":[],"advisors":["Juurlink, Bernhard","Wu, L."],"committee_chairs":[],"committee_members":["Richardson, J. Steven","Wang, Hui Di","Kulyk, W.","Desai, K.","Lee, P."],"year":2011,"date_issued":"2011-03","date_published":"2011-03","updated_at":"2026-07-24T04:26:49Z","subjects":["SHRsp","sulforaphane","hypertension","phase2 protein inducer"],"languages":["en_US"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/10388/etd-03292011-144232","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Juurlink, Bernhard","Wu, L."]},{"key":"dc:contributor.committeemember","label":"Committee Member","values":["Richardson, J. Steven","Wang, Hui Di","Kulyk, W.","Desai, K.","Lee, P."]},{"key":"dc:creator","label":"Author","values":["Banigesh, Ali"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2011-03-29T14:42:32Z","2013-01-04T04:27:31Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2012-04-06T08:00:00Z","2013-01-04T04:27:31Z"]},{"key":"dc:date.issued","label":"Date","values":["2011-03"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Pharmacology"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Doctoral"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy (Ph.D.)"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Saskatchewan"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["SHRsp","sulforaphane","hypertension","phase2 protein inducer"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/10388/etd-03292011-144232"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Persistent hypertension is associated with a greater incidence of organ damage and conditions such as stroke, heart failure and end–stage kidney disease, which results in increased cardiovascular (CV) morbidity and mortality. Among the patients receiving antihypertensive treatment, the level of adequate blood pressure (BP) control ("]},{"key":"dc:title","label":"Title","values":["Antihypertensive effects of sulforaphane"]}]}],"canonical_facts":{"dc:contributor.advisor":["Juurlink, Bernhard","Wu, L."],"dc:contributor.committeemember":["Richardson, J. Steven","Wang, Hui Di","Kulyk, W.","Desai, K.","Lee, P."],"dc:creator":["Banigesh, Ali"],"dc:date.accessioned":["2011-03-29T14:42:32Z","2013-01-04T04:27:31Z"],"dc:date.available":["2012-04-06T08:00:00Z","2013-01-04T04:27:31Z"],"dc:date.issued":["2011-03"],"dc:description.abstract":["Persistent hypertension is associated with a greater incidence of organ damage and conditions such as stroke, heart failure and end–stage kidney disease, which results in increased cardiovascular (CV) morbidity and mortality. Among the patients receiving antihypertensive treatment, the level of adequate blood pressure (BP) control ("],"dc:identifier.uri":["https://hdl.handle.net/10388/etd-03292011-144232"],"dc:language.iso":["en_US"],"dc:subject":["SHRsp","sulforaphane","hypertension","phase2 protein inducer"],"dc:title":["Antihypertensive effects of sulforaphane"],"thesis:degree_discipline":["Pharmacology"],"thesis:degree_level":["Doctoral"],"thesis:degree_name":["Doctor of Philosophy (Ph.D.)"],"thesis:institution_name":["University of Saskatchewan"]},"updated_at":"2026-07-24T04:26:49Z"}